IGF1R and colorectal carcinoma: In this study, we demonstrated that the novel IGF1-R inhibitor PB-020 and the multi-target compound MBZ can synergistically reduce the viability of CRC cells and block xenograft CRC progress, which is accompanied by the synergistic down-regulation of the pAKT1-S473 level.